Travel Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Composition (Mono Vaccines v/s Combination Vaccines), By Disease Indication (Hepatitis A, DPT, Yellow Fever, Typhoid, Hepatitis B, Measles and Mumps, Rabies, Meningococcal, Varicella, Japanese Encephalitis, Others), By Travel Type (Domestic v/s International) and By Region 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 6.81 Billion
CAGR (2026-2031)	9.22%
Fastest Growing Segment	Hepatitis A
Largest Market	North America
Market Size (2031)	USD 11.56 Billion

Market Overview

The Global Travel Vaccine Market will grow from USD 6.81 Billion in 2025 to USD 11.56 Billion by 2031 at a 9.22% CAGR. Travel vaccines are biological preparations administered to individuals intending to travel to specific regions to provide acquired immunity against endemic infectious diseases. The expansion of this market is primarily driven by the robust resurgence of international tourism and strict government mandates requiring immunization for visa approvals. This growth is further supported by rising global disposable incomes which facilitate increased cross-border mobility and business travel. According to UN Tourism, in 2024, international tourist arrivals reached 96 percent of pre-pandemic levels during the first seven months, indicating a substantial recovery in global movement that directly correlates with the heightened demand for prophylactic healthcare measures.

Despite these positive growth indicators, the market faces significant impediments regarding the complex logistics required for vaccine distribution. The stringent cold chain storage requirements create high operational costs and distribution inefficiencies, particularly in developing nations with limited infrastructure. Consequently, these supply chain constraints represent a substantial challenge that could restrict the widespread accessibility of essential immunizations and impede the overall expansion of the global travel vaccine sector.

Key Market Drivers

The resurgence of global international tourism and business travel acts as a primary catalyst for market expansion, as increased mobility directly correlates with a higher volume of vaccine administration. As air connectivity improves and borders fully reopen, travelers are increasingly venturing into exotic and tropical locations where endemic diseases pose significant health risks, thereby necessitating prophylactic immunization. This upward trajectory in mobility ensures a sustained patient pool for travel medicine clinics and pharmaceutical manufacturers, specifically for vaccines protecting against hepatitis A, typhoid, and yellow fever. According to the International Air Transport Association, July 2024, in the 'Air Passenger Market Analysis', total international passenger demand rose by 14.6 percent in May 2024 compared to the same month in the previous year, highlighting the rapid recovery of cross-border movement that underpins market demand.

Concurrently, the escalating prevalence of emerging and re-emerging infectious diseases in popular tourist destinations compels travelers to seek vaccination prior to departure. Outbreaks of vector-borne illnesses in tropical regions have heightened the urgency for preventative measures among tourists and business expatriates, driving the adoption of newly approved immunization options. For instance, the significant expansion of dengue fever transmission areas has created acute demand for preventative solutions. According to the Pan American Health Organization, March 2024, in the 'Epidemiological Update Dengue', the Americas region reported over 3.5 million suspected cases of dengue in early 2024, marking a staggering increase compared to historical averages. This epidemiological landscape translates into tangible financial gains for vaccine developers. According to Bavarian Nordic, in 2024, the company reported that its Travel Health segment achieved a revenue of DKK 1,877 million for the full year of 2023, reflecting the robust commercial impact of high infection risks on the market.

Download Free Sample Report

Key Market Challenges

The complex logistics and stringent cold chain storage requirements constitute a formidable barrier to the growth of the Global Travel Vaccine Market. Travel vaccines are biological products that typically demand precise temperature controls, ranging from refrigerated to cryogenic states, throughout their entire transit. In regions with underdeveloped infrastructure, maintaining this thermal continuity is both operationally difficult and financially burdensome. The resulting high operational costs and elevated risk of product spoilage deter manufacturers and distributors from efficiently expanding into these markets. Consequently, this logistical fragility effectively places a ceiling on revenue potential, as the industry struggles to guarantee the reliable availability of essential immunizations in destinations where they are most needed.

This operational strain is further intensified by the immense volume of products that must navigate these often-constrained supply networks. The pressure to move vast quantities of temperature-sensitive vials amplifies existing distribution inefficiencies. According to UNICEF's Supply Annual Report 2024, the organization managed the international delivery of 2.787 billion vaccine doses to 99 countries in 2024. Processing such a massive volume through fragile cold chains inevitably leads to bottlenecks and supply interruptions. These constraints directly restrict market reach and undermine the industry's capacity to fully capitalize on the heightened demand for prophylactic healthcare driven by the resurgence of global tourism.

Key Market Trends

The Commercialization of Novel Vaccines for Vector-Borne Diseases is shifting the market from research to the availability of approved prophylactics for neglected tropical illnesses. Developers are navigating regulatory pathways to launch immunizations for diseases like chikungunya, filling the preventative care gap for travelers visiting endemic regions. This transition from pipeline to product generates immediate commercial value and expands the travel health portfolio beyond traditional vaccines. According to Bavarian Nordic A/S, November 2025, in the 'Interim Results for the First Nine Months of 2025', Travel Health revenue increased by 23 percent to DKK 2,327 million, a growth trajectory supported by the commercial launch of its chikungunya vaccine, Vimkunya.

Concurrently, the Development of Multivalent and Combination Vaccine Formulations is reshaping immunization strategies by offering broad-spectrum protection through single-product solutions. Manufacturers are prioritizing tetravalent technologies that induce immunity against multiple virus serotypes simultaneously, simplifying vaccination schedules and enhancing traveler compliance compared to monovalent alternatives. This innovation improves clinical outcomes and drives market uptake by streamlining the logistical burden for travel medicine providers. According to Takeda Pharmaceutical Company Limited, January 2025, in the 'earnings results for the third quarter of fiscal year 2024', the company reported that its tetravalent dengue vaccine, Qdenga, generated 19.9 billion JPY in revenue for the first half of the fiscal year, marking an 863 percent increase.

Segmental Insights

The Hepatitis A segment constitutes the fastest-growing area of the global travel vaccine market, largely due to rising tourism in regions where waterborne diseases are prevalent. This growth is reinforced by health advisories from institutions like the Centers for Disease Control and Prevention, which strongly recommend vaccination for travelers visiting destinations with lower sanitation standards. As international mobility increases and travelers prioritize preventive health measures based on these authoritative guidelines, the demand for Hepatitis A vaccines experiences a corresponding and significant expansion.

Regional Insights

North America currently leads the Global Travel Vaccine Market, driven by high consumer awareness regarding infectious diseases and a robust healthcare infrastructure. The region benefits significantly from increasing outbound tourism and strict immunization recommendations issued by established regulatory bodies such as the Centers for Disease Control and Prevention. Additionally, the presence of major pharmaceutical manufacturers and comprehensive insurance coverage facilitates broad access to preventive medical care. These factors, combined with rising disposable incomes that support international travel, create a sustained demand for travel-related immunizations, thereby cementing North America's dominant position in the global landscape.

Recent Developments

• In February 2025, Bavarian Nordic received approval from the U.S. Food and Drug Administration for its recombinant chikungunya vaccine, Vimkunya. This milestone established the product as the first vaccine for the prevention of chikungunya disease approved for individuals as young as 12 years of age. The approval relied on comprehensive clinical trials showing strong immunogenicity and safety in both adolescents and adults. This development significantly expanded the options available for travel health, allowing for the protection of a broader age range of travelers visiting regions where the chikungunya virus is endemic.
• In December 2024, Valneva reported positive three-year antibody persistence data for its single-shot chikungunya vaccine, Ixchiq. The research demonstrated that 96% of participants maintained neutralizing antibody levels well above the seroresponse threshold 36 months after receiving the vaccination. These results confirmed the vaccine's ability to induce a robust, durable immune response across various age groups, including older adults. The data reinforced the product's profile as a long-term preventative solution for the mosquito-transmitted disease, supporting its use for travelers requiring sustained protection. The findings were consistent with previous reports and highlighted the vaccine's efficacy durability.
• In July 2024, Valneva received marketing authorization from the European Commission for Ixchiq, its single-dose chikungunya vaccine. This approval marked the first licensure of a chikungunya vaccine in Europe, indicated for adults over the age of 18 at increased risk of exposure to the mosquito-borne virus. The authorization was valid in all 27 European Union member states, as well as Iceland, Liechtenstein, and Norway. The vaccine addressed a significant unmet medical need for travelers and those living in endemic areas, providing a new preventative tool against a disease characterized by severe joint pain.
• In February 2024, Takeda announced a strategic partnership with Biological E. Limited to accelerate global access to its dengue tetravalent vaccine, Qdenga. This collaboration focused on manufacturing multi-dose vials to support national immunization programs, aiming to produce up to 50 million doses annually. The agreement was designed to aid Takeda's objective of delivering 100 million doses per year by 2030, specifically addressing the growing public health threat in endemic regions. By leveraging combined manufacturing capabilities, the partners aimed to ensure a sustainable supply of the vaccine for procurement by governments and public health agencies worldwide.

Key Market Players

• GlaxoSmithKline, plc
• Sanofi S.A.
• Novartis International AG
• Merck KGaA
• Pfizer Inc.
• AstraZeneca Plc
• Abbott Laboratories, Inc
• F. Hoffmann-La Roche AG
• CSL Limited
• Johnson & Johnson

By Composition	By Disease Indication	By Travel Type	By Region
Mono Vaccines v/s Combination Vaccines	Hepatitis A DPT Yellow Fever Typhoid Hepatitis B Measles and Mumps Rabies Meningococcal Varicella Japanese Encephalitis Others	Domestic v/s International	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Travel Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Travel Vaccine Market, By Composition:

• Mono Vaccines v/s Combination Vaccines

• Travel Vaccine Market, By Disease Indication:

• Hepatitis A
• DPT
• Yellow Fever
• Typhoid
• Hepatitis B
• Measles and Mumps
• Rabies
• Meningococcal
• Varicella
• Japanese Encephalitis
• Others

• Travel Vaccine Market, By Travel Type:

• Domestic v/s International

• Travel Vaccine Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE